Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4Small Cell Lung Carcinoma 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Leukemia 2Sezary Syndrome 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Multiple Myeloma 1Melanoma 1Mastocytosis, Systemic 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Lung Neoplasms 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Leukemia, Biphenotypic, Acute 1Intraocular Lymphoma 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1

Interventions

Carboplatin 340Cisplatin 238Paclitaxel 203Radiotherapy 195Pemetrexed 187Docetaxel 169Gemcitabine 157pembrolizumab 141Erlotinib Hydrochloride 107Etoposide 99Magnetic Resonance Spectroscopy 93Bevacizumab 91Specimen Handling 76Nivolumab 73Radiosurgery 72durvalumab 69Vinorelbine 54osimertinib 53Gefitinib 49Drug Therapy 49atezolizumab 42Irinotecan 42Radiation 40Topotecan 39Biopsy 39Standard of Care 38Cyclophosphamide 38Cetuximab 35Blood Specimen Collection 33Taxes 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lung Neoplasms × obatoclax × Clear all
NCT00405951 2016-07-21

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1/2 Completed
47 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡